Stephen Baylin, M.D.
Co-leader, Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team
VAI–SU2C Epigenetics Dream Team
Primary appointment: Johns Hopkins University
Dr. Stephen Baylin earned his M.D. from Duke University in Durham, N.C. in 1968 and completed his internship and first year of residency at the university. He then served as a staff associate at the National Institutes of Health’s National Heart and Lung Institute for two years before returning to Johns Hopkins to complete his residency and fellowship. He was appointed as an assistant professor of medicine at Johns Hopkins in 1974 and rose through the ranks, becoming a professor of oncology in 1986 and a professor of medicine in 1990. In 1991, he was appointed chief of the Tumor Biology Division and, the following year, was named as the associate director for research at the Johns Hopkins Oncology Center. He is currently Virginia and D.K. Ludwig Professor for Cancer Research in the Oncology Department and co-head of Cancer Biology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr. Baylin has earned numerous prestigious honors, including the 2004 Investigator of the Year Award from NCI SPORE; the 2005 Shubitz Cancer Research Prize from the University of Chicago; and the 2009 Kirk A. Landon-AACR Prize for Basic and Translational Cancer Research, together with Van Andel Institute (VAI) Chief Scientific Officer Dr. Peter A. Jones. In 2011, Drs. Baylin and Jones were jointly awarded the American Cancer Society’s Medal of Honor. He was elected to the National Academy of Sciences in 2017.
He has authored or co-authored more than 450 publications and served as associate editor of Cancer Research. Dr. Baylin also served on the board of the American Association for Cancer Research Board of Directors from 2004 to 2007, and was the leader of the first SU2C Epigenetics Dream Team, launched in 2009.
He has received numerous honors and accolades, including the 2011 American Cancer Society Medal of Honor, which he shared with Dr. Peter A. Jones; election as a fellow of the American Association of Cancer Research Academy in 2014; and election as a member of the National Academy of Sciences in 2017.
In 2015, he accepted an appointment at VAI as co-leader of the VAI–SU2C Epigenetics Dream Team, which he leads with Dr. Jones, and as a professor in the Center for Epigenetics. In addition to his work at VAI, Dr. Baylin continues his work at Johns Hopkins